What is DMRA's Value Score?

Damora Therapeutics, Inc. - Common Stock (DMRA) has a StockPik Value Score of 25 out of 100 — a low score, indicating weak value characteristics. The Value Score is a composite ranking built from P/E ratio, P/B ratio, Graham Number, ROE, gross margin, debt-to-equity, current ratio, and Piotroski F-Score, calculated from SEC EDGAR annual filing data.

What is DMRA's Piotroski F-Score?

Damora Therapeutics, Inc. - Common Stock (DMRA) has a Piotroski F-Score of 2 out of 9 — a weak score indicating financial deterioration across multiple criteria. The F-Score assesses nine binary financial criteria across profitability, leverage, and operating efficiency. A score of 7–9 indicates a financially improving company; a score of 0–3 is a warning sign.

What is DMRA's Piotroski F-Score?

DMRA's Piotroski F-Score is 2 out of 9, indicating weak financial health and possible deterioration. The Piotroski F-Score evaluates nine criteria across profitability, leverage, and operating efficiency. Scores of 7 or above are considered strong; 3 or below indicate financial weakness.

Is DMRA (Damora Therapeutics, Inc. - Common Stock) undervalued?

DMRA scores 25/100 on StockPik's Value Score.

Back to Screener

Damora Therapeutics, Inc. - Common Stock (DMRA)

NASDAQ Small Cap

$25.09

Market Cap: $1.5B

Data as of Sep 30, 2025 (TTM)

Investment Snapshot

P/B of 6.29 — trading above book value
Piotroski F-Score 2/9 — signs of financial weakness
Loss-making — negative ROE of -5.4%

Damora Therapeutics, Inc. - Common Stock (DMRA) is a publicly traded company, listed on the NASDAQ , with a market capitalisation of $1.5 billion . Key value metrics: P/B ratio 6.29, Piotroski F-Score 2 out of 9 .

Value Score

out of 100

Try PRO Free — See Full Breakdown

Key Metrics

P/E Ratio

—

P/B Ratio

6.29

EPS

$-0.22

Div. Yield

—

PEG Ratio

—

P/S Ratio

—

EV/EBITDA

—

ROE

—

ROA

—

Gross Margin

—

Op. Margin

—

Net Margin

—

Debt/Equity

—

Current Ratio

—

Unlock 19 More Metrics — 7 Days Free

Data sourced from SEC EDGAR and Polygon.io. Methodology.

Damora Therapeutics, Inc. - Common Stock — Fundamental Analysis Summary

On financial health, DMRA shows a weak Piotroski F-Score of 2/9, a signal of deteriorating financial health, and negative return on equity of -5.4%.

StockPik's composite Value Score for DMRA is 25/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.

DMRA shows earnings declining at 879%.

How is the Value Score calculated?

Read our full methodology →

What is the Piotroski F-Score?

The 9-point financial health score explained, with worked examples →

DMLP — DORCHESTER MINERALS, L.P.

DIGIMARC CORPORATION — DMRC